








242Phase II Study of Risk-Adapted Therapy of Newly
Diagnosed, Aggressive Non-Hodgkin Lymphoma Based
on Midtreatment FDG-PET Scanning
Yvette L. Kasamon, Richard L. Wahl, Harvey A. Ziessman, Amanda L. Blackford,
Steven N. Goodman, Caroline A. Fidyk, Kathryn M. Rogers, Javier Bolan˜os-Meade,
Michael J. Borowitz, Richard F. Ambinder, Richard J. Jones, Lode J. SwinnenIn newly diagnosed aggressive non-Hodgkin lymphoma (NHL), a positive midtreatment fluorine-18 fluoro-
deoxyglucose positron emission tomography (PET) scan often carries a poor prognosis, with reported 2-
year event-free survival (EFS) rates of 0% to 30% after standard therapy. To determine the outcome of early
treatment intensification for midtreatment PET-positive disease, a phase II trial of risk-adapted therapy was
conducted. Fifty-nine newly diagnosed patients, 98%with B cell lymphoma, had PET/CT performed after 2 or
3 cycles of first-line chemotherapy. Those with negative PETon semiquantitative visual interpretation com-
pleted standard therapy. Those with positive PETreceived platinum-based salvage chemotherapy, high-dose
therapy, and autologous stem cell transplantation (ASCT). Midtreatment PETwas positive in 33 (56%); 28
received ASCTwith an actuarial 2-year EFS of 75% (95% confidence interval, 60%-93%). On intention-to-
treat analysis, 2-year EFS was 67% (53%-86%) in all PET-positive patients and 89% (77%-100%) in PET-negative
patients. No association was found between the International Prognostic Index category and the midtreat-
ment PET result. The favorable outcome achieved here in historically poor-risk patients warrants further,
more definitive investigation of treatment modification based on early PET scanning.
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tationINTRODUCTION
Fluorine-18 fluorodeoxyglucose positron emission
tomography (FDG-PET), when performed after only
2 to 3 cycles of first-line chemotherapy, is highly
prognostic in aggressive non-Hodgkin lymphoma
(NHL)[1-5]. A positive midtreatment PET during ini-
tial therapy has been retrospectively associated with 2-
year progression-free or event-free survival (EFS) rates
of 0% to 30%, compared with 72% to 93% if the mid-
treatment scan is negative [2,3,5]. The prognostic sig-
nificance of midtreatment PET has been repeatedly
recognized without the use of biopsy [1-7]. How to
utilize the prognostic information provided by PETJohns Hopkins University, Baltimore, Maryland.
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trials of risk-adapted therapy for aggressive NHL
based on early PET.
Study outcomes of autologous stem cell transplan-
tation (ASCT) as part of initial therapy have been
mixed [8,9]. Early ASCT is controversial, but appears
to benefit the subset with poor-risk features [8,10,11],
defined traditionally by the International Prognostic
Index (IPI) [12]. For example, in a randomized study,
overall survival (OS) was significantly greater after
CHOP (cyclophosphamide [Cy], vincristine, doxoru-
bicin, prednisone) plus ASCT than after CHOP alone
in patients with high-intermediate risk disease [8].
Midtreatment PET may be a stronger and more indi-
vidualized prognostic tool than pretreatment indices
[2,3]. We hypothesized that a suboptimal metabolic
response, as identified by midtreatment PET, is a re-
flection of chemoresistance and an indication for treat-
ment intensification. Thus, we investigated whether
early intensification with platinum-based chemother-
apy then ASCT could change the natural history of
midtreatment PET-positive disease, recognizing that
comparison of phase II data with historic data cannot
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tant to explore practical aspects of PET interpretation
and management, and to evaluate this novel strategy in
a phase II setting before considering a large-scale ran-
domized trial.METHODS
Study Design
A phase II study (J0348) was activated at Johns
Hopkins in February 2004, and 59 patients accrued
through April 2007. The study was approved by the
institutional review board, and all participants gave in-
formed consent. The study accrued patients aged$18
years with measurable, aggressive NHL who had
received no more than 3 cycles of standard first-line
chemotherapy. To maximize feasibility, patients were
permitted to join after treatment had been initiated.
The original protocol permitted diffuse large B cell,
follicular grade 3, and peripheral T cell lymphomas.
The study was later limited to diffuse large B cell lym-
phoma because the others were infrequent. Primary
central nervous system, transformed, and human im-
munodeficiency virus (HIV)-associated lymphomas
were excluded. Pathology materials in all cases were
reviewed by members of the Johns Hopkins Division
of Hematopathology.
All who joined had midtreatment PET/CT in ad-
dition to conventional restaging. A baseline PET scan
was not required, but when available was used for com-
parison. Midtreatment PET/CT was performed be-
tween days 11 and 20 of cycle 2 or 3 using
a dedicated fusion PET/CT scanner at JohnsHopkins,
acquiring 3-dimensional images in 2-dimensional
mode. After a minimum 4-hour fast, 18F-FDG (typi-
cally 0.22mCi/kg) was injected intravenously provided
that the glucose was\200 mg/dL. Following an ap-
proximately 60-minute uptake phase, CT for attenua-
tion correction and lesion localization was performed
[13]. Emission data were then acquired from the base
of the skull to the mid-femurs (5 to 7 bed positions,
5 minutes per position). Both CT attenuation cor-
rected and noncorrected images were available.
One of 2 nuclear medicine specialists evaluated all
PET scans for study purposes. The PET was inter-
preted qualitatively and the result dichotomized as
‘‘negative’’ (no evidence of malignant disease) or ‘‘pos-
itive’’ (focal or diffuse uptake in an area suspicious for
a residual or new focus of malignancy) [2]. Within this
designation, tumor FDG uptake relative to mediasti-
nal blood pool structures was graded on a 5-point
scale: 0, no tumor activity (cold); 11, minimal (less
than background); 21, equivocal (equal to back-
ground); 31, moderate (greater than background);
41, intense (much greater than background) [14].
Scores of 31 or 41 were considered positive.Patients with negative midtreatment PET com-
pleted the remaining standard therapy, without early
ASCT. In the absence of progression, those with pos-
itive midtreatment PET received 2 cycles of ESHAP
(etoposide, methylprednisolone, high-dose cytarabine,
cisplatin) or ICE (ifosfamide, carboplatin, etoposide)
with rituximab added for B cell tumors, then stem
cell collection during the second cycle followed by
high-dose therapy and ASCT. Two patients with pos-
itive midreatment PET received an extra cycle of
R-CHOP for logistic reasons before changing thera-
pies. Biopsies of abnormally FDG avid areas were
not performed. Radiation therapy after ASCTwas per-
missible. A PET/CTwas repeated 4 to 6 weeks follow-
ing chemotherapy completion, prior to any radiation.
High-Dose Therapy
Eligibility requirements for ASCT included ab-
sence of clinically evident disease progression;
ECOG performance status #2; neutrophils .1000/
mm3, platelets $75,000/mm3, creatinine #2.0 mg/
dL, and bilirubin #2.0 mg/dL (unless because of Gil-
bert’s disease or lymphoma) prior to mobilization; and
adequate cardiac and pulmonary function.
Autografts were derived from peripherally mobi-
lized stem cells or, if the yield was\2  106 CD341
cells/kg ideal body weight, from bone marrow harvest
(n 5 2). Stem cells were mobilized with filgrastim 10
mg/kg/day s.c. begun after the second cycle of
(R)ESHAP or (R)ICE. A 2- to 6-hour leukapheresis
was performed once the absolute CD341 cell count
was .10/mL. Products of $5  106 CD341 cells/kg
were positively selected for CD34 using the Isolex
system. All but 1 transplant utilized a preparative reg-
imen consisting of busulfan (Bu; 1mg/kg every 6 hours
for 4 days, with dose adjustments based on pharmaco-
kinetic calculations), followed by Cy (50 mg/kg/day
for 4 days) [15]. Filgrastim was given from day 5 until
neutrophil recovery.
Statistical Analysis
We estimated that a minimum of 19 transplants
was required to achieve at least 85% power to detect
an absolute 25% increase in 2-year EFS in midtreat-
ment PET-positive patients, assuming a 2-year EFS
of 20% historically in midtreatment PET-positive pa-
tients who did not receive early ASCT and a 1-sided
type I error of 5%. EFS and OS were estimated using
the Kaplan-Meier method [16]. Survival was measured
from the date of first chemotherapy or from day 0 for
transplant outcomes. An event was defined as relapse
or progression, diagnosis of myelodysplastic syndrome
(MDS) or acute leukemia, or death. Cumulative inci-
dence of progression or relapse was estimated using
a competing risks analysis, where nonrelapse deaths
and secondary hematologic cancers were competing





patients (n 5 28)
Median age at diagnosis (range) 53 (20-78) 46 (21-66)
Male sex 39 17
Histology
Diffuse large B cell or large B cell 56 (95%) 27 (96%)
Primary mediastinal 10 8
Follicular grade 3 2 0














Low or low-intermediate 36 18
Midtreatment PET positive 21 (58%) —
High-intermediate or high‡ 20 9
Midtreatment PET positive 11 (55%) —
First-line chemotherapy
R-CHOP 21 56 26
R-CHOP 14 2 1
CHOP 21 1 1
Timing of midtreatment PET
Cycle 2 20 9
Cycle 3§ 39 (66%) 19 (68%)
Midtreatment PET result




Positive 33 (56%) 28
3+ 18 16
4+ 15 12
Salvage regimen (if PET positive)
(R)ESHAP  2 — 13
R-ICE  2 — 12





Peripheral blood — 26










Radiation after ASCT — 4
Posttransplant PET negative 3
Posttransplant PET positive 1
ASCT indicates autologous stem cell transplantation; Bu-Cy, busulfan-
cyclophosphamide; Cy-TBI, cyclophosphamide and total body irradia-
tion; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone;
ESHAP, etoposide, methylprednisolone, high-dose cytarabine, cisplatin;
ICE, ifosfamide, carboplatin, etoposide; PET, positron emission tomog-
raphy; R, rituximab; IPI, international prognostic index.
*Baseline bone marrow biopsy was not performed in 4 patients diag-
nosed as stage II, 1 as stage III, and 3 as stage IV.
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were analyzed using proportional hazards models for
competing risks [18]. All P-values are 2-sided. Statisti-
cal analyses were performed with R, version 2.6.0 [19],
and represent data through October 2, 2008.RESULTS
Overall Outcomes
Baseline characteristics are shown in Table 1.
Ninety-five percent of patients had large B cell lym-
phoma, and 97% of patients received (R)CHOP-21
with the remaining 3% receiving R-CHOP-14.
Twenty-six of 59 patients (44%) were interpreted as
having negative midtreatment PET and 33 (56%) as
having positive midtreatment PET. Corresponding
PET scan scale readings, ranging from 0 through
41, are provided.
Table 2 presents the actuarial survival outcomes
for all patients and separately for the 56 patients with
large B cell lymphoma, of whom 32 (57%) had positive
midtreatment PET. The median follow-up for all
patients is 33.6 months (range: 1.3-54.5 months) and
37.2 months for surviving patients. The estimated
2-year EFS of the entire cohort is 77% and 2-year
OS is 82%.
Outcomes of the PET-Positive Cohort
Of 33 patients with a positive midtreatment PET,
28 (85%) received ASCT. Two PET-positive patients
withdrew consent and were censored on the midtreat-
ment PET date. Three were ineligible because of dis-
ease progression prior to planned ASCT. Figure 1A
presents an intention-to-treat survival analysis from
the time of treatment initiation.
The median follow-up after ASCT is 34.1 months
overall (range: 1.3-49.7 months) and 36.0 months for
surviving patients. Outcomes are shown in Figure 1B
and Table 2, with an estimated 2-year EFS after
ASCT of 75% and estimated 3-year EFS of 65%. In
PET-positive patients having a score of 41, the
2-year EFS after ASCT is 67%.
On last assessment, 19 of 28 transplant recipients
were event free. Six progressed or relapsed, including
the 1 patient with T cell lymphoma, at a median of 3.2
months (range: 1.0-29.4 months). Four of these had
died. There were 3 nonrelapse deaths as described
shortly.†Excluding patients with follicular grade 3 or T cell lymphoma.
‡IPI scores in this group ranged from 3 to 4.
§Includes 2 patients with PET during both cycle 2 and cycle 3, with read-
ing changed in 1; results for cycle 3 reported. Another patient received
cyclophosphamide initially because of hyperbilirubinemia, with PET dur-
ing cycle 3 of R-CHOP.
¶Because of nephotoxicity (n5 2) or gastrointestinal symptoms (n5 1).
^Becauseof death fromearly progression (n52) or from toxicity (n51).
=
Table 2. Actuarial Survival and Competing-Risk Progression Analysis
Cohort n Event-Free Survival (95% CI) Overall Survival (95% CI)
Cumulative Incidence
of Progression or Relapse (95% CI)
All 59 2 y: 77% (67-89), 3 y: 69% (57-83) 2 y and 3 y: 82% (73-93) 2 y: 18% (8-28), 3 y: 23% (11-35)
Midtreatment PET negative 26 2 y: 89% (77-100), 3 y: 82% (66-100) 2 y and 3 y: 92% (83-100) 2 y: 8% (0-18), 3 y: 14% (0-31)
Midtreatment PET positive
(intention-to-treat)
33 2 y: 67% (53-86), 3 y: 59% (43-80) 2 y and 3 y: 74% (60-91) 2 y: 26% (10-42), 3 y: 31% (13-48)
Midtreatment PET positive, after
transplantation
28 2 y: 75% (60-93), 3 y: 65% (49-87) 2 y: 82% (69-98), 3 y: 76%
(61-96)
2 y: 18% (3-33), 3 y: 23% (6-40)
Large B cell lymphoma 56 2 y: 76% (65-88), 3 y: 70% (58-84) 2 y and 3 y: 81% (72-93) 2 y: 19% (8-30), 3 y: 22% (10-33)
Midtreatment PET negative 24 2 y: 88% (75-100), 3 y: 80% (64-100) 2 y and 3 y: 92% (81-100) 2 y: 8% (0-20), 3 y: 16% (0-33)
Midtreatment PET positive
(intention-to-treat)
32 2 y: 66% (51-86), 3 y: 62% (47-83) 2 y and 3 y: 73% (59-91) 2 y and 3 y: 27% (11-43)
Midtreatment PET positive,
after transplantation
27 2 y: 74% (59-93), 3 y: 69% (53-90) 2 y: 81% (68-97), 3 y:
75% (59-95)
2 y and 3 y: 19% (4-34)
PET indicates positron emission tomography; CI, confidence interval; y, year(s).
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The estimated 2-year and 3-year EFS of patients
with negativemidtreatmentPETare 89%and82%, re-
spectively (Figure 1C and Table 2). In the absence of
events, all completed full-course therapy, with none re-
ceiving more than 6 chemotherapy cycles. Of the 26
PET-negative patients, 4 (15%) have had documented
relapse or progression to date. Formal comparison be-
tween the PET-positive and PET-negative cohorts is
not intended because of the differences in therapy.Predictors of Outcome
As a planned secondary analysis, we explored clin-
ical variables at presentation in relation to the mid-
treatment PET result (positive versus negative). We
found no association between the IPI, scored as low
or low-intermediate versus high-intermediate or
high, and the midtreatment PET result (P . .99). Of
the 56 patients with large B cell lymphoma, 36 had
an IPI #2, of whom 15 (42%) had negative midtreat-
ment PET. Of 20 patients with IPI $3, 9 (45%) had
negative midtreatment PET, of whom 7 were last
event free (1 leukemia death, 1 relapse). The estimated
3-year EFS is 78% (65%-94%) with IPI #2 disease
and 57% (37%-85%) with IPI $3 disease. Among
midtreatment PET-positive patients, there tended to
be a greater risk of progression or relapse in those
with IPI $3 (hazard ratio [HR] 3.6; 95% confidence
interval, 0.9-14.2; P 5 .07). Outcomes according to
PET result and IPI are shown in Figure 2.
There was no statistically significant association
found between the midtreatment PET result and ei-
ther stage (I-II versus III-IV) or histology (primary
mediastinal versus other large B cell lymphoma), al-
though a larger percentage of patients with primary
mediastinal lymphoma had positive PET (80% versus
52%). Patients .50 years were significantly more
likely to have negative midtreatment PET (P\ .01),
including those with nonmediastinal large B cell
lymphomas.A planned exploratory analysis of the impact of
gradations of FDG uptake on outcome was per-
formed. We hypothesized that, within the binary des-
ignation of a ‘‘positive’’ or ‘‘negative’’ scan, the
intensity of remaining FDG uptake might be prog-
nostic. In the PET-negative group, survival curves
for a midtreatment PET score of 0 or 11 versus 21
were superimposable (not shown); however, there
were too few events to discriminate differences.
Within the PET-positive group, there tended to be
greater risk of progression or relapse in patients hav-
ing a score of 41 versus 31 (Figure 1D), although the
result was not statistically significant (HR 2.9, P5 .13
for all histologies; HR 2.5, P 5 .19 for large B cell
lymphoma).
Major Toxicities
In the PET-negative group, 1 died of leukemia. Of
the 28 transplanted PET-positive patients, 1 died at
1.4 months of hepatic veno-occlusive disease, and an-
other developed self-limited veno-occlusive disease; 1
died at 9.9 months frommultiple strokes and pneumo-
nia, with negative evaluations for lymphoma; and 1 de-
veloped MDS and died after nonmyeloablative
allogeneic transplantation.DISCUSSION
We report encouraging phase II results with
a novel, individualized, risk-adapted strategy for newly
diagnosed aggressive NHL based on early metabolic
imaging. The estimated 2-year EFS of 75% (67% on
intention-to-treat analysis) in midtreatment PET-pos-
itive patients suggests that early treatment intensifica-
tion, as carried out in our study, may improve the
outcome of this historically poor-risk group. Our
data also support prior observations of the favorable
prognostic significance of a negative midtreatment
PET scan, with excellent outcomes to date after R-
CHOP alone.
Figure 1. Outcomes according to midtreatment PETresult. (A) Intention-to-treat analysis of EFS of patients with positive midtreatment PET. (B) EFS of
patients with positive midtreatment PET who received early transplantation. (C) EFS of patients with negative midtreatment PET. (D) Cumulative
incidence of progression or relapse in all patients with positive midtreatment PET, according to PET scale score of 31 versus 41.
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PET-positive patients are expected to be better than
those reported historically. Midtreatment PET is,
however, prognostic whether or not the regimen in-
cludes rituximab [4].
PET performed after 2 or 3 cycles of first-line che-
motherapy, as done in this study, appears to be optimal
for prognostication [3,4]. Most studies of the prognos-
tic significance of PET have been based on visual
(qualitative) assessments. Our criteria for a positive
or negative scan are similar to the recently proposed
International Harmonization Project criteria [20],
which this study predated. However, FDG uptake on
a PET scan is a continuous variable, and criteria for
a ‘‘positive’’ or ‘‘negative’’ result have varied in the lit-
erature [3,20,21]. In this regard, the high rate of PET
positivity in our patients with primary mediastinal
lymphoma is notable; additional study is required to
define whether the prognostic significance of PET dif-
fers in this histologic subtype. The meaning of the as-
sociation between older age and having a negative
midtreatment PET result is unclear in this limited da-
taset. We took a conservative approach to PET inter-pretation, with the many cases that might be regarded
as ‘‘borderline’’ (score 21) treated as negative. A pro-
spective trial of PET in lymphoma response assess-
ment is evaluating a cutoff of 1.5 times blood pool
activity for differentiating between positive and nega-
tive results [22]. Our imaging analysis suggests that
the intensity of residual FDG uptake may have further
prognostic significance.
Biopsy of FDG avid lesions was not performed in
this study. Importantly, however, midtreatment PET
does not require corroboration with biopsy to be prog-
nostic, as the consistently strong prognostic value of
PET has been recognized without biopsy data
[1-5,23]. Biopsy is subject to sampling error, even if
guided by PET. Although false positive PET results
are possible, the role of biopsy as a potential solution
to that problem is not established.
Moskowitz et al. [24] recently conducted a promis-
ing phase II study of advanced diffuse large B cell lym-
phoma, involving dose-dense R-CHOP,midtreatment
PET, then ICE, with ASCT reserved for PET-positive
patients having biopsy confirmation [24]. Only 4 of 31
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Figure 2. Outcomes according to midtreatment PETresult and International Prognostic Index (IPI). (A) Midtreatment PET-negative cohort. (B) Mid-
treatment PET-positive cohort. Abbreviations: MDS, myelodysplastic syndrome; n/a, not applicable; PD, progressive disease.
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did not significantly differ by PET result; however, all
patients received treatment intensification through
a change to ICE. The use of R-ICE as intensification
for midtreatment PET-positive disease is being inves-
tigated in ECOG. It has additionally been suggested
that the false positive rate of midtreatment PET in-
creases after rituximab-containing therapy because of
inflammation [25]. Prospective observational studies
will address this question.
Despite the reasonable follow-up in this study
(median 3 years after ASCT), additional follow-up
will be needed to determine whether the apparent
improvement in the PET-positive group is sustained.
Although our results are encouraging, our single-
institution study has several limitations including
potential referral bias, lack of requirement for a base-
line PET (which may reduce the accuracy of response
assessment), and recruitment of some patients after
treatment initiation. Permitting registration after
treatment initiation could, however, select either for
or against better-risk disease. Of note, the distribution
of patients by age, stage, and IPI risk category is very
similar to larger published series of patients with
aggressive lymphoma [12,26]. We further examined
outcome stratified by a good-risk versus poor-risk re-
vised IPI and found similar outcomes to those reported
by Sehn et al. [26] with R-CHOP. The number of
patients in our study does not permit a more rigorous
examination of this question.
Preemptive treatment intensification remains con-
troversial. Results of a phase III U.S. Intergroup studycomparing ASCT versus observation after full-course
R-CHOP in IPI $2 disease should inform future ap-
proaches in this regard. In our study, 9 patients had
both a high IPI and negative midtreatment PET,
with generally good overall outcomes to date without
treatment intensification. Although analysis is limited,
this might suggest that on an individual basis, a nega-
tive midtreatment PET is reliable in high IPI disease.
It may be that risk-assessment strategies incorporating
both the IPI and early PET scanning will ultimately
prove to be the most informative.
Our results suggest that midtreatment PET scan-
ning is useful in guiding therapy, and that such individ-
ualized therapy is feasible. The relative contribution of
ASCT compared with a platinum- and etoposide-
containing salvage regimen, and to what degree early
ASCT affects survival in midtreatment PET-positive
patients, are ultimately phase III questions. Further in-
vestigations of individualized, risk-adapted strategies
based on early metabolic imaging are warranted.ACKNOWLEDGMENTS
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